Robert Jan Veldman Ph.D.

After completion of his study Medical Biology at Utrecht University, Robert Jan performed his PhD-project in Groningen (and in part at the University of Michigan, Ann Arbor, USA) on sphingolipid signaling in cancer cells, in relation to multidrug-resistance. He continued this line of research during a two-year post-doc project at INSERM in Toulouse, France. After subsequent post-doc projects at the Netherlands Cancer Institute (liposomal delivery of chemotherapeutic agents) and the Academic Medical Centre (gene therapy for correction of inherited lipid disorders) in Amsterdam, Robert Jan joined the Utrecht University for Applied Sciences in 2005. In addition to his general molecular- and cell biological skills, Robert Jan is an expert on the metabolism and biological activity of lipids. His leisure activities include speed skating and scuba diving.




Veldman RJ, van Blitterswijk WJ, Verheij M, Koning GA

Pharmaceutical formulations employing short-chain sphingolipids and their use.

United States Patent and Trademark Office (2006), European Patent Office (2006)


PUBLICATIONS (selection out of 27 papers; H-factor 15)

Vaessen SF, Veldman RJ, Comijn EM, Snapper J, Sierts JA, vd Oever K, Beattie SG, Twisk J, Kuivenhoven JA

AAV gene therapy as a means to increase apolipoprotein A-1 and high-density lipoprotein cholesterol levels: correction of murine apoA-1 deficiency.

J. Gene Med. 11: 697-707 (2009)

Veldman RJ, Koning GA, van Hell A, Zerp S, Vink SR, Storm G, Verheij M, van Blitterswijk WJ

Coformulated N-octanoyl-glucosylceramide improves cellular delivery and cytotoxicity of liposomal doxorubicin.

J. Pharmacol. Exp. Ther. 315: 704-710 (2005)

Gajate C, del Canto-Jañez E, Ulises-Acuña A, Amat-Guerri F, Geijo E, Santos-Beneit A, Veldman RJ, Mollinedo F

Intracellular triggering of Fas aggregation and recruitment of apoptotic molecules into Fas-enriched rafts in selective tumor cell apoptosis.

J. Exp. Med. 200: 353-365 (2004)

Veldman RJ, Zerp S, van Blitterswijk WJ, Verheij M

N-hexanoyl-sphingomyelin potentiates in vitro doxorubicin cytotoxicity by enhancing its cellular influx.

Br. J. Cancer 90: 917-925 (2004)

Veldman RJ, Mita A, Cuvillier O, Garcia V, Klappe K, Medin JA, Campbell JD, Carpentier S, Kok JW, Levade T

The absence of functional glucosylceramide synthase does not sensitize melanoma cells for anti-cancer drugs.

FASEB. J. 17: 1144-1146 (2003)

Veldman RJ, Klappe K, Hinrichs J, Hummel I, van der Schaaf G, Sietsma H, Kok JW

Altered sphingolipid metabolism in multidrug resistant ovarian cancer cells is due to uncoupling of glycolipid biosynthesis in the Golgi apparatus.

FASEB J. 16: 1111-1113 (2002)

Veldman RJ, Maestre N, Aduib OM, Salvayre R, Medin JA, Levade T

A neutral sphingomyelinase resides in sphingolipid-enriched microdomains and is inhibited by the caveolin-scaffolding domain: potential implications in tumour necrosis factor signalling.

Biochem. J. 355: 859-868 (2001)

Sietsma H, Veldman RJ, Kok JW

The involvement of sphingolipids in multidrug resistance.

J. Membr. Biol. 181: 153-162 (2001)

Veldman RJ, Sietsma H, Klappe K, Hoekstra D, Kok JW

Inhibition of P-glycoprotein activity and chemosensitization of multidrug-resistant ovarium carcinoma 2780AD cells by hexanoylglucosylceramide.

Biochem. Biophys. Res. Comm. 266: 492-496 (1999)

Veldman RJ, Klappe K, Hoekstra D, Kok JW

Interferon γ-induced differentiation and apoptosis of HT29 cells; dissociation of (glucosyl)ceramide signaling.

Biochem. Biophys. Res. Comm. 247: 802-808 (1998)

Veldman RJ, Klappe K, Hoekstra D, Kok JW

Metabolism and apoptotic properties of elevated ceramide in HT29rev cells.

Biochem. J. 331: 563-569 (1998)





Lecturer / Scientist / Project leader